{
    "organizations": [],
    "uuid": "af088557c0c70f4ad42761f328ed553103e3c33c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-cantargias-european-patents-for-bo/brief-cantargias-european-patents-for-both-leukemia-and-solid-tumours-remain-valid-after-appeal-period-ends-idUSFWN1SA1GO",
    "ord_in_thread": 0,
    "title": "BRIEF-Cantargia's European Patents For Both Leukemia And Solid Tumours Remain Valid After Appeal Period Ends",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Cantargia AB:\n* CANTARGIA’S EUROPEAN PATENTS FOR BOTH LEUKEMIA AND SOLID TUMOURS REMAIN VALID AFTER APPEAL PERIOD ENDS\n* CO’S EUROPEAN PATENTS COVERING ANTIBODY TREATMENT OF LEUKEMIA AS WELL AS SOLID TUMOURS WILL REMAIN IN FORCE BASED ON EPO COMMUNICATION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-04T14:36:00.000+03:00",
    "crawled": "2018-05-05T12:21:53.059+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "cantargia",
        "ab",
        "cantargia",
        "european",
        "patent",
        "leukemia",
        "solid",
        "tumour",
        "remain",
        "valid",
        "appeal",
        "period",
        "end",
        "co",
        "european",
        "patent",
        "covering",
        "antibody",
        "treatment",
        "leukemia",
        "well",
        "solid",
        "tumour",
        "remain",
        "force",
        "based",
        "epo",
        "communication",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}